Clinical Trials
34 trialsAlemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis
M.D. Anderson Cancer Center
Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL
Eastern Cooperative Oncology Group
Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia
Eastern Cooperative Oncology Group
Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia
National Institutes of Health Clinical Center (CC)
A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL
Northwestern University
Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies
M.D. Anderson Cancer Center
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies
St. Jude Children's Research Hospital
Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia
Mayo Clinic
ALBUM
University of Arizona
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
New York Medical College
Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
University of California, San Francisco
Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML
OHSU Knight Cancer Institute
Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)
M.D. Anderson Cancer Center
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
University of Arizona
Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
Alliance for Clinical Trials in Oncology
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
M.D. Anderson Cancer Center
Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors
University of Arizona
Alemtuzumab + Rituximab Consolidation in CLL
M.D. Anderson Cancer Center
Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia
Stanford University
Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayo Clinic
Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia
Sanofi
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
Northside Hospital, Inc.
Alemtuzumab in Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond to Previous Fludarabine
National Cancer Institute (NCI)
LLC0405
Gruppo Italiano Malattie EMatologiche dell'Adulto
Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission
National Cancer Institute (NCI)
Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
CFAR Study in Patients With Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
Memorial Sloan Kettering Cancer Center
MPDMDSBMT
Baylor College of Medicine
Alemtuzumab and Pentostatin In T-cell Neoplasms
M.D. Anderson Cancer Center
Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia
Mayo Clinic
Campath-1H + FK506 and Methylprednisolone for GVHD
Case Comprehensive Cancer Center
Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
CRC005
Chronic Lymphocytic Leukemia Research Consortium